Skip to content
Europe PMC: new psychedelic research papers· Novick AM, Love TM, Johnson RL, Page CE, Effinger DP, Sukenik D, Bishop K, Calderone J, Scott J, Haller H, Turow L, Soffer H, Vonesh L, Allen MH, Fischer SM, Sammel MD, Epperson CN, Thompson SM.·· 21 days agoAI score55

Psilocybin with psychological support for anhedonia in treatment-resistant depression: a randomised controlled pilot trial

Effects of psilocybin with psychological support on anhedonia in treatment-resistant depression: A randomized controlled pilot trial.

AI summary

A randomised, double-blindA study in which neither participants nor the researchers assessing them are told who received which treatment.Open the glossary, placebo-controlledA study that compares the treatment with an inactive or low-dose look-alike, called a placebo.Open the glossary pilot trial in 20 participants with treatment-resistant major depressive disorder found no statistically significant between-group difference in anhedonia at the primary week 1 endpoint, with a DARS change difference of 11.2 (95% CI, -1.0 to 23.3; p = 0.073) for psilocybin 25 mg versus 1 mg, both given with psychological support.

Key facts

Kind of item
Papers
Compound
Psilocybin
Condition
Depression
Jurisdiction
United States
Participants
20 participants (as written in the text)
Source
Europe PMC: new psychedelic research papers (europepmc.org)
Published
How this summary was made

The summary was written by an AI model from the linked source, and a model scored the item against this site's editorial criteria. The facts above come from the item's topics and from identifiers written out in the stored text. Anything not found there is left out, so a missing row means not stated, not no. Read the original before relying on any detail. Editorial method

Source: Europe PMC: new psychedelic research papers · europepmc.org

Connected to

Kind of item
Papers
Compound
Psilocybin
Condition
Depression
Jurisdiction
United States

Other recent items on these topics